News
CDMO
12.30
-0.24%
-0.03
Avid Bioservices, Inc. Proposes Transaction with GHO Capital Partners and Ampersand Capital, Encouraging Stockholder Support
Barchart · 3d ago
AVID BIOSERVICES RECOMMENDS STOCKHOLDERS VOTE FOR VALUE MAXIMIZING TRANSACTION
Reuters · 3d ago
AVID BIOSERVICES INC: SPECIAL MEETING TO VOTE ON TRANSACTION SCHEDULED FOR JAN 30, 2025
Reuters · 3d ago
Weekly Report: what happened at CDMO last week (1209-1213)?
Weekly Report · 5d ago
Avid Bioservices Reports Revenue Growth Amid Acquisition Plans
TipRanks · 12/12 03:50
Craig-Hallum Sticks to Its Hold Rating for Avid Bioservices (CDMO)
TipRanks · 12/11 13:46
Avid Bioservices Reports 32% Revenue Growth Ahead Of Acquisition
NASDAQ · 12/11 10:49
Avid Bioservices: Fiscal Q2 Earnings Snapshot
Barchart · 12/11 04:03
Avid Bioservices, Inc. Reports Second Quarter Fiscal 2025 Financial Results and Announces Merger Agreement with GHO and Ampersand Capital Partners
Barchart · 12/11 01:22
Avid Bioservices Inc reports results for the quarter ended October 31 - Earnings Summary
Reuters · 12/10 22:14
Avid Bioservices Q2 EPS $(0.27) Misses $(0.12) Estimate, Sales $33.50M Miss $33.80M Estimate
Benzinga · 12/10 21:23
Avid Bioservices reports Q2 EPS (27c), consensus (10c)
TipRanks · 12/10 21:21
*Avid Bioservices Suspending Practice of Providing Fincl Guidance in Light of Proposed Transaction >CDMO
Dow Jones · 12/10 21:13
*Avid Bioservices 2Q Rev $33.5M >CDMO
Dow Jones · 12/10 21:12
*Avid Bioservices 2Q Loss/Shr 27c >CDMO
Dow Jones · 12/10 21:12
AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR SECOND QUARTER ENDED OCTOBER 31, 2024
Reuters · 12/10 21:05
AVID BIOSERVICES INC: WILL NOT HOST AN EARNINGS CONFERENCE CALL AND IS SUSPENDING ITS PRACTICE OF PROVIDING FINANCIAL GUIDANCE.
Reuters · 12/10 21:05
AVID BIOSERVICES Q2 REVENUE USD 33.5 MILLION VS. IBES ESTIMATE USD 33.8 MILLION
Reuters · 12/10 21:05
Press Release: Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
Dow Jones · 12/10 21:05
More
Webull provides a variety of real-time CDMO stock news. You can receive the latest news about Avid Bioservices through multiple platforms. This information may help you make smarter investment decisions.
About CDMO
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.